Merck’s Q3 earnings hit $5.23B, powered by Keytruda and Januvia, and the firm’s new $120M Blackstone partnership pushes sacituzumab‑tirumotecan toward Phase 3.

Novartis unveils Phase‑III success for Fabhalta and Vanrafia, showing significant proteinuria and BP reductions while preserving kidney function—boosting investor confidence and reshaping nephrology treatment.

Teva launches “The Other TD” campaign to raise awareness of tardive dyskinesia, boosting early‑detection diagnostics and strengthening value‑based payer relationships.

Carrier Global’s HVAC dominance is underpinned by a 12 % cycle‑time cut, 18 % fewer downtimes, and a $3.1 B 2025 CapEx plan, yet analysts cut near‑term targets amid rising competition.

Canadian Pacific Kansas City Limited’s latest investor deck shows solid 2024 growth, margin gains and a 15 % CAPEX push, but highlights data gaps, rising fuel risk, and new USMCA digital freight challenges that could shape its North American freight…

Grab Holdings Q3 earnings show revenue and EBITDA growth, fueled by group ride‑hailing and GrabFoodPlus subscriptions, while regulators and rivals challenge its super‑app strategy.

Explore how BMO’s new Credit Coach app and Burgundy Asset acquisition could boost revenue, deepen customer ties, and navigate regulatory risks—all in one strategic move.

Explore Astellas Pharma’s Q2 2026 & FY 2025 earnings transcripts—see how its urology, oncology, immunology and metabolic therapies drive growth, R&D investment, and strategic roadmap.

JD Sports’ steady growth shows how a sportswear retailer leverages Gen Z, athleisure and eco‑friendly tech to thrive amid energy‑price shocks and changing consumer trends.

Skanska AB gears up for a November earnings call, unveiling €820 million of sustainable construction in Poland, leadership changes, and tech‑driven productivity gains that promise stronger EPS and a strategic edge in European green infrastructure.